Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 60,677 Shares

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 60,677 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider owned 59,086 shares in the company, valued at approximately $2,779,996.30. This represents a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The shares were sold at an average price of $27.30, for a total value of $142,560.60.

Urogen Pharma Trading Down 1.5%

Shares of NASDAQ URGN opened at $46.16 on Tuesday. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81. The stock’s fifty day simple moving average is $40.82 and its two-hundred day simple moving average is $29.32. The stock has a market capitalization of $2.26 billion, a PE ratio of -23.31 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, equities analysts predict that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Urogen Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd acquired a new stake in Urogen Pharma in the 2nd quarter worth approximately $66,000. Quantbot Technologies LP acquired a new position in Urogen Pharma during the 2nd quarter valued at approximately $78,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after purchasing an additional 486 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares during the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on URGN. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Guggenheim lifted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. HC Wainwright boosted their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.38.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.